大规模类器官来源的囊肿培养作为多囊肾病药物发现平台
本研究建立了一种可规模化的悬浮培养方案,将野生型和PKD2缺陷型hiPSC来源的肾单位类器官转化为输尿管芽(UB)类器官,后者可高效形成囊肿。利用该平台筛选小分子库,发现TLR4拮抗剂M1可减小囊肿,且TAK-242减少而脂多糖增加囊肿形成,提示TLR4驱动囊肿生成。
要点
- 悬浮培养7天内可从约50个肾单位类器官扩增至2000个UB类器官。
- PKD2缺陷型UB类器官约20天达高效成囊,囊肿表达ADPKD标志物。
- 囊肿对JQ1和QNZ敏感,但对托伐普坦不敏感,与AVPR2低表达一致。
核心结论
- 建立可规模化的UB类器官悬浮培养方法,为ADPKD药物发现提供简单高效平台。
- PKD2缺陷型UB类器官可高效形成囊肿,并用于化合物筛选。
- TLR4拮抗剂M1和TAK-242减少囊肿形成,脂多糖增加囊肿形成。
研究设计与样本
- 将野生型和PKD2缺陷型hiPSC来源的第12天肾单位类器官解离为单细胞,在悬浮培养中经UB增殖条件诱导形成UB类器官。
- 通过免疫组化、RT-qPCR和单细胞RNA测序对UB类器官进行表征。
- 进行为期十天的化合物筛选,从明场图像定量囊肿数量和直径。
- 筛选小分子库以验证平台作为药物发现工具的可行性。
主要发现
- 该方案可规模化,7天内从约50个肾单位类器官产生多达2000个UB类器官。
- UB类器官表达UB特异性标志物AQP2、WNT9B和KRT8,并具有管状延伸。
- PKD2缺陷型UB类器官在7天内启动囊肿形成,约20天时成囊效率很高。
- 囊肿表达ADPKD标志物,并对JQ1和QNZ有反应,但对托伐普坦无反应,与AVPR2低表达一致。
- 小分子库筛选鉴定出M1(推定TLR4拮抗剂)可减小囊肿大小;TAK-242减少囊肿形成,脂多糖增加囊肿形成。
关键数值与推荐
- 7天内从约50个肾单位类器官产生多达2000个UB类器官。
- PKD2缺陷型UB类器官在7天内启动囊肿形成,约20天时成囊效率很高。
- 化合物筛选为期十天,从明场图像定量囊肿数量和直径。
- 囊肿对JQ1和QNZ有反应,但对托伐普坦无反应,与低AVPR2表达一致。
临床怎么用
- 该平台可用于ADPKD候选药物的高通量筛选。
- 筛选时需注意PKD2缺陷型囊肿对托伐普坦不敏感,与AVPR2低表达相关。
- TLR4通路可作为ADPKD囊肿形成的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the slow, progressive formation of fluid-filled cysts within the kidneys, ultimately leading to kidney failure. Despite being the most common genetic kidney disease, therapies for ADPKD are limited. Ureteric bud (UB) organoids derived from human induced pluripotent stem cells (hiPSC) have been developed to model ADPKD. Here, we describe a protocol to generate UB organoids in large-scale suspension culture amenable to drug discovery. METHODS: Day 12 'nephron' organoids derived from wild-type and PKD2-deficient hiPSC lines were dissociated into single cells and exposed to UB-propagating growth conditions in suspension culture, leading to formation of organoids with UB-like identity (UB organoids). Wild-type and cyst-forming PKD2-deficient UB organoids were characterized by immunohistochemistry, RT-qPCR, and single-cell RNA-sequencing. Compound screening for cyst reduction was performed over a ten-day period, with cyst number and diameter quantified from brightfield images. RESULTS: UB organoids generated by our protocol are readily scalable, yielding up to 2000 organoids from approximately 50 nephron organoids within seven days. They exhibit tubular extension alongside the expression of UB-specific markers, including AQP2, WNT9B, and KRT8. PKD2-deficient UB organoids initiate cystogenesis within seven days, achieving very high cyst-forming efficiency by about 20 days. The cysts express ADPKD markers and respond to cyst-reducing compounds, including the bromodomain inhibitor JQ1 and the NF-κB inhibitor QNZ, but not tolvaptan, consistent with low AVPR2 expression. To validate the platform as a drug discovery tool, we screened a small-molecule library and identified M1, a putative Toll-like receptor 4 (TLR4) antagonist, that reduces cyst size. Consistent with TLR4-driven cystogenesis, the investigational TLR4 inhibitor TAK-242 reduced cyst formation, whereas lipopolysaccharide increased cyst formation. CONCLUSIONS: We have developed a scalable method to generate cystic UB organoids, providing a simple and efficient platform for ADPKD drug discovery.
引用
- Vanichapol T, Wangford R, Mishra S, et al. Large-scale organoid-derived cyst cultures as a drug discovery platform for polycystic kidney disease. Kidney Int. 2026. PMID: 42772449. doi:10.1016/j.kint.2026.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。